ライフサイエンスコーパス: atenolol

1 r CAS (verapamil sustained release) or NCAS (atenolol).

2 th agonists given together with 1 micromol/L atenolol).

3 reduce left ventricular (LV) mass more than atenolol.

4 after beta-adrenergic receptor blockade with atenolol.

5 e selective beta(1)-adrenoceptor antagonist, atenolol.

6 aily double-blind treatment with losartan or atenolol.

7 essure was reduced similarly by losartan and atenolol.

8 ion and to control his ventricular rate with atenolol.

9 antidepressant venlafaxine, and beta-blocker atenolol.

10 st entirely on the conventional beta-blocker atenolol.

11 icated hypertension comes from studies using atenolol.

12 ainly by the emerging deleterious effects of atenolol.

13 baroreflex as it persists in the presence of atenolol.

14 Atenolol (0.1 microM), a selective beta1-AR antagonist,

15 er intravenous injections: saline (control), atenolol (0.2 mg/kg, beta-adrenergic blockade), atropine

16 Furthermore, atenolol (0.5 microg) blocked the memory-enhancing effec

17 nfusions of the beta-adrenoceptor antagonist atenolol (0.5 microgram in 0.2 microliter) into the ipsi

18 e-anaesthetized, artificially ventilated and atenolol (1 mg kg(-1))-pretreated cats.

19 captopril (25 mg/kg body weight per day) or atenolol (10 mg/kg body weight per day) for 8 weeks.

20 The selective beta 1-adrenergic antagonist atenolol (10(-6) M) did not affect terbutaline-induced d

21 In the second phase, atenolol 100 mg was added to amlodipine and isosorbide 5

22 ne 1.25 mg, hydrochlorothiazide 6.25 mg, and atenolol 12.5 mg).

23 ration was by dose doubling, and addition of atenolol 25-50 mg or enalapril 5-10 mg.

24 or matching placebo, and the step 2 drug is atenolol (25-50 mg) or matching placebo.

25 ent with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d) added if necessary to maintain goa

26 thalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)

27 s reduced by 25% with losartan compared with atenolol, 25.1 vs 35.4 events per 1000 patient-years (re

28 rothiazide (59% versus 34%, P<0.001) but not atenolol (27% versus 22%, NS).

29 mg digoxin, 2) 240 mg diltiazem-CD, 3) 50 mg atenolol, 4) 0.25 mg digoxin + 240 mg diltiazem-CD, and

30 CAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide;

31 lowering drugs (hydrochlorthiazide, 12.5 mg; atenolol, 50 mg; ramipril, 5 mg) at low doses, simvastat

32 neal injection (metoprolol, 100 mg x kg(-1); atenolol, 6 mg x kg(-1)) or central nervous system beta1

33 goxin + diltiazem: 67.3+/-14.1 and digoxin + atenolol: 65.0+/-9.4.

34 oxin: 78.9 +/- 16.3, diltiazem: 80.0+/-15.5, atenolol: 75.9+/-11.7, digoxin + diltiazem: 67.3+/-14.1

35 beta-AR blockers (carvedilol, metoprolol, or atenolol), 9 from patients with heart failure without be

36 he lowest doses of rate-control medications; atenolol: 92 mg versus 68 mg; carvedilol: 44 mg versus 2

37 (a nonspecific beta-adrenergic antagonist), atenolol (a beta1-adrenergic antagonist), or zinterol (a

38 Neither atenolol, a beta 1-specific adrenergic antagonist, prazo

39 in secretion, and this effect was blocked by atenolol, a selective beta(1)-adrenergic antagonist.

40 Blockade of beta-adrenergic receptors with atenolol abolished the pup-induced heart rate increase,

41 etic blockade: Atropine, given alone or with atenolol, abolished nearly all RR-interval variability a

42 group (n=3294) included patients initiating atenolol, acebutolol, or metoprolol.

43 tenolol was transformed almost completely to atenolol acid.

44 2-propanolmethanesulphonate (CGP 20712A) and atenolol act as classic antagonists at the catecholamine

45 Inhibition was also seen following atenolol administration.

46 vere chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adve

47 ffects of amlodipine, whereas the effects of atenolol and amlodipine were not additive.

48 fate (0.04 mg/kg, parasympathetic blockade), atenolol and atropine (complete autonomic blockade), and

49 and twice under combined autonomic blockade (atenolol and atropine sulfate) conditions.

50 Adizem XL) and the combination of amlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitr

51 sociation studies may predict BP response to atenolol and hydrochlorothiazide when assessed through r

52 rug (high stereoselectivity was recorded for atenolol and MDMA), treatment technology used (activated

53 Nifedipine GITS, atenolol and placebo were administered to 15 subjects wi

54 rom trials of traditional beta-blockers (eg, atenolol and propranolol), because there are currently n

55 ion CT scanner after premedication with oral atenolol and/or intravenous metoprolol.

56 of 0.1-1.3 h(-1) for MCPA, 2,4-D, mecoprop, atenolol, and diclofenac, corresponding to half-lives of

57 of a variety of drugs including propranolol, atenolol, and ibuprofen has been developed.

58 tricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to

59 release compartments containing pravastatin, atenolol, and ramipril.

60 2.0 (SD 13.7) and 1.3 (SD 12.1) beats/min in atenolol- and amlodipine-based groups, respectively.

61 Both nifedipine GITS and atenolol are effective at preventing mental stress-induc

62 d by 28/9 and 28/9 mm Hg in the losartan and atenolol arms.

63 metabolic and genetic mechanisms underlying atenolol-associated adverse metabolic effects.

64 Ds were abolished by beta(1)-antagonism with atenolol at therapeutic concentration (1 mum).

65 norepinephrine (NE) alone (10 mcmol/L) or NE+atenolol (AT) (10 mcmol/L) for 12 hours.

66 olymer (MIP)-based ultrathin film using R(+)-atenolol (ATNL) as a template was reported.

67 edical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placeb

68 tion drug regimen than in those allocated an atenolol-based combination drug regimen (HR 0.86 and 0.7

69 ct of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in

70 approximately 1 year after randomization to atenolol-based or amlodipine-based antihypertensive trea

71 r in patients on the atenolol-based regimen: atenolol-based regimen, 7.9 +/- 1.8; amlodipine-based re

72 P) (mean +/- SD) was similar in both groups: atenolol-based regimen, systolic BP of 137 +/- 17 mm Hg,

73 olic function than patients treated with the atenolol-based regimen.

74 were significantly higher in patients on the atenolol-based regimen.

75 lic relaxation, was lower in patients on the atenolol-based regimen: atenolol-based regimen, 7.9 +/-

76 tension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG

77 PLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hyperten

78 er a verapamil sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control.

79 ssigned to a verapamil sustained-release- or atenolol-based strategy; blood pressure control and outc

80 cated amlodipine-based therapy compared with atenolol-based therapy (unadjusted hazard ratio: 0.81, p

81 hat the superiority of amlodipine-based over atenolol-based therapy for patients with hypertension un

82 The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients wi

83 ective central aortic pressure lowering with atenolol-based therapy versus amlodipine-based therapy i

84 t and Sokolow-Lyon voltage criteria than did atenolol-based therapy.

85 tage (-2.5 versus -0.7 mm, P<0.001) than was atenolol-based therapy.

86 4, and 5 years of blinded losartan-based or atenolol-based therapy.

87 Losartan- or atenolol-based treatment regimens, with follow-up assess

88 Losartan- or atenolol-based treatment regimens, with follow-up assess

89 n in patients with ECG LVH than conventional atenolol-based treatment.

90 mized to a mean of 4.8 years of losartan- or atenolol-based treatment.

91 ardiogram, randomly assigned to losartan- or atenolol-based treatment.

92 Nebivolol/bendrofluazide and atenolol/bendrofluazide each lowered the clinic blood pr

93 r the same degree of blood pressure control, atenolol/bendrofluazide had no effect on nitric oxide bi

94 ean+/-SEM], 435+/-27%, P<0.001) but not with atenolol/bendrofluazide.

95 a second experiment, intra-BLA infusions of atenolol (beta-adrenoceptor antagonist) and Rp-cAMPS (cA

96 oceptor antagonists (propranol, beta1/beta2; atenolol, beta1; ICI 118551; beta2; 100 microm), or by t

97 artery disease on beta-blocker therapy with atenolol, bisoprolol, or metoprolol underwent adenosine

98 ficance (P<0.05), and 3 were associated with atenolol BP response at P<0.01.

99 The genetic score of the atenolol BP-lowering alleles was associated with respons

100 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem (sustained rel

101 g) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochloroth

102 g) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochloroth

103 librated using measured photolysis rates for atenolol, carbamazepine, propranolol, and sulfamethoxazo

104 ased significantly with hydrochlorothiazide, atenolol, clonidine, and diltiazem at 1 year and with al

105 t under systemic beta-adrenoceptor blockade (atenolol) combined with spinal cord (C1) transection (to

106 tions suggest inhibition is most relevant at atenolol concentrations greater than approximately 200 n

107 Results suggest that the role of AOB in atenolol degradation may be disproportionately more sign

108 eutical compounds loratadine, oxycodone, and atenolol deposited on glass, wood, steel, and polyester

109 resonant laser vaporization of oxycodone and atenolol desorbed from steel is 2.4% +/- 1.5% and 0.25%

110 Acetylsalicylic acid, acetaminophen, atenolol, diclofenac, and ibuprofen were tested as targe

111 Atenolol did not block the stimulatory effects of epinep

112 At 1 year, use of added open-label atenolol, diuretics, angiotensin-converting enzyme inhib

113 er(II)-bound complexes of seven model drugs (atenolol, DOPA, ephedrine, pseudoephedrine, isoprotereno

114 t undergo noncardiac surgery, treatment with atenolol during hospitalization can reduce mortality and

115 riment 2), or the beta1-receptor antagonist, atenolol (Experiment 3).

116 nabling rapid 1H NMR spectral acquisition of atenolol (experimental time of 10 s) without obstruction

117 sive Responses (PEAR) study and treated with atenolol for 9 weeks, we prospectively followed a nested

118 se data suggest that losartan is superior to atenolol for treatment of patients with isolated systoli

119 from 70% for hydrochlorothiazide to 92% for atenolol for younger white men, and from 84% for hydroch

120 The hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in

121 cITP successfully isolates the atenolol from the sucrose while concentrating it 200-fol

122 so lower in the amlodipine group than in the atenolol group (all p<0.0001).

123 t in the placebo group and 83 percent in the atenolol group (P=0.008).

124 e (mean [+/-SD] age, 11.5+/-6.5 years in the atenolol group and 11.0+/-6.2 years in the losartan grou

125 ore did not differ significantly between the atenolol group and the losartan group (-0.139+/-0.013 an

126 as lower in the amlodipine group than in the atenolol group at all follow-up visits (p<0.0001), mainl

127 sit variability in SBP were increased in the atenolol group compared with both the placebo group and

128 ty in blood pressure during follow-up in the atenolol group correlated with trends in stroke risk.

129 Ninety-nine were assigned to the atenolol group, and 101 to the placebo group.

130 in the amlodipine group and increased in the atenolol group.

131 .01) compared with the diabetic control, but atenolol had no significant effect.

132 strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertens

133 a treatment strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained

134 (verapamil) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care stra

135 .4 microL injection of 200 microM (1.9 nmol) atenolol in a 1000-fold excess of sucrose (200 mM) is an

136 atenolol) for the primary end point favored atenolol in black patients (1.666 [95% confidence interv

137 d a randomized trial comparing losartan with atenolol in children and young adults with Marfan's synd

138 conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardio

139 ar disease, losartan was more effective than atenolol in preventing cardiovascular morbidity and deat

140 mlodipine enhanced P-selectin expression and atenolol increased fibrinogen binding in response to ago

141 Atenolol inhibited both responses (SSS, P = 0.003; L-glu

142 fusions of the beta1-adrenoceptor antagonist atenolol into either the hippocampus (1.25 microg in 0.5

143 When ISO plus the beta(1)-AR antagonist atenolol (ISO-beta(2)-AR stimulation) or 1 microM zinter

144 metoprolol (highly permeable compounds) and atenolol (low-moderate permeability compound) were orall

145 95% confidence limits, -61.0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.

146 During summer, atenolol, metoprolol, and propranolol were rapidly atten

147 The fate of three selected beta blockers-atenolol, metoprolol, and sotalol-was examined during ni

148 oval mechanism in the pilot-scale system for atenolol, metoprolol, and trimethoprim, while sulfametho

149 e control during exercise and while at rest: atenolol, metoprolol, diltiazem, and verapamil (drugs li

150 intervals (CIs) for first cardiac events for atenolol, metoprolol, propranolol, and nadolol were 0.71

151 ry who were prescribed common beta-blockers (atenolol, metoprolol, propranolol, or nadolol).

152 rtan (n = 173) than in patients treated with atenolol (n = 254) (relative risk, 0.69 [CI, 0.57 to 0.8

153 to receive once-daily losartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the secon

154 lex, beta(2)-AR stimulation (salbutamol plus atenolol) of I(Ca,L) was examined in pertussis toxin-tre

155 a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in t

156 omparison with beta-blockers, the effects of atenolol on cardiovascular hemodynamics were examined, w

157 4-year trial of the effect of lacidipine or atenolol on echographic carotid intima-media thickness.

158 is by comparing the effects of nebivolol and atenolol on endothelial function.

159 astrointestinal therapeutic system (GITS) or atenolol on ischemic left ventricular dysfunction induce

160 the impact of treatment with losartan versus atenolol on outcomes, ECG strain remained a significant

161 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg

162 f chlorthalidone (step 1); either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be add

163 verapamil and 8361 received either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide.

164 noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.1

165 curred in the COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR]

166 -verapamil group (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (HR, 1.54

167 nd 7.1 mm Hg for partcipants assigned to the atenolol or hydrochlorothiazide group.

168 ssociation of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hyper

169 propranolol, and LTM dogs received placebo, atenolol, or amlodipine.

170 g ECG, were treated in a blinded manner with atenolol- or losartan-based regimens, and were followed

171 pertension) treated in a blinded manner with atenolol- or losartan-based regimens.

172 xin (p < 0.0001), diltiazem (p < 0.0002) and atenolol (p < 0.001).

173 delayed with regimens 3 and 5 which included atenolol (p < 0.03).

174 Losartan decreased ECG-LVH more than atenolol (P<.001) and was better tolerated.

175 ring alleles was associated with response to atenolol (P=3.3 x 10(-6) for systolic BP; P=1.6 x 10(-6)

176 Therapy with either nifedipine GITS or atenolol prevented the development of wall-motion abnorm

177 Digoxin + atenolol produced the most effective rate control reflec

178 Our results using atenolol, salbutamol, and cocaine as test compounds show

179 r to demonstrate enantiomeric separations of atenolol, serine, methionine, threonine, methyl alpha-gl

180 ntrol on captopril, hydrochlorothiazide, and atenolol show a reduction of LV mass after 1 year of tre

181 The beta1-specific antagonist, atenolol, significantly decreased latency to attack (1 m

182 ol were dose-dependent and not observed with atenolol; similar effects were observed with apocynin, a

183 ere evaluated for five drugs: carbamazepine, atenolol, sulfamethazine, diazepam, and alprazolam.

184 py reduced ischemia further, with amlodipine/atenolol superior to diltiazem (Adizem XL)/isosorbide 5-

185 th persistence of the benefit of losartan vs atenolol therapy on developing AF (HR, 0.83; 95% CI, 0.7

186 Regression of ECG LVH with losartan versus atenolol therapy was assessed in 9193 hypertensive patie

187 Atenolol therapy was associated with lower baseline and

188 impact of 2 different BP lowering-regimens (atenolol+/-thiazide-based versus amlodipine+/-perindopri

189 Quantitative measurements of atenolol, tioconazole, tetraethylammonium bromide, and t

190 ocardiograms in 457 losartan-treated and 459 atenolol-treated participants with > or =1 follow-up mea

191 tients (17.5 per 1000 patient-years) and 355 atenolol-treated patients (21.8 per 1000 patient-years;

192 red in 125 losartan-treated patients and 193 atenolol-treated patients (relative risk, 0.66 [CI, 0.53

193 red in 103 losartan-treated patients and 132 atenolol-treated patients (relative risk, 0.80 [CI, 0.62

194 red in 110 losartan-treated patients and 100 atenolol-treated patients (relative risk, 1.14 [CI, 0.87

195 e hospital was significantly lower among the atenolol-treated patients than among those who were give

196 ar outcomes were similarly reduced among the atenolol-treated patients; event-free survival throughou

197 ment of impaired fasting glucose (IFG) after atenolol treatment.

198 During exercise, digoxin and digoxin + atenolol treatments resulted in the highest and lowest m

199 nths of lisinopril therapy, the beta-blocker atenolol was added to lisinopril for another three month

200 When atenolol was added, it rose significantly and returned t

201 Atenolol was begun at a dose of 12.5 mg daily and increa

202 Atenolol was given intravenously before and immediately

203 Biodegradation of atenolol was observed and linked to the activity of ammo

204 Atenolol was observed to competitively inhibit AOB growt

205 The VR on digoxin + atenolol was significantly lower than that on digoxin (p

206 Amlodipine/atenolol was significantly superior during the drug-free

207 Atenolol was transformed almost completely to atenolol a

208 me who were randomly assigned to losartan or atenolol, we found no significant difference in the rate

209 f glyceryl trinitrate (GTN), amlodipine, and atenolol were studied in nine normal volunteers.

210 diltiazem-CD, and 5) 0.25 mg digoxin + 50 mg atenolol; were studied after 2 week treatment assigned i

211 ine, plus adjunctive hydrochlorothiazide and atenolol when needed to control blood pressure, both had

212 Conversely, atenolol, when added to lisinopril, achieved maximum hem

213 was also inhibited by high- but not low-dose atenolol, whereas collagen content was not elevated with

214 were prevented by cotreatment with high-dose atenolol (which nearly fully inhibited isoproterenol-ind

215 and shorter transit distance in contrast to atenolol, which was absorbed more slowly from more dista

216 ol with 2.5 mg of bendrofluazide or 50 mg of atenolol with 2.5 mg of bendrofluazide.

217 om baseline to the last available study than atenolol with adjustment for baseline LVMI and blood pre

218 bo-controlled trial to compare the effect of atenolol with that of a placebo on overall survival and